EDX Medical Group PLC Director dealing (2603Y)
02 Gennaio 2024 - 8:00AM
UK Regulatory
TIDMEDX
RNS Number : 2603Y
EDX Medical Group PLC
29 December 2023
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation No 596/2014
which is part of English law by virtue of the European (Withdrawal)
Act 2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
Director dealing
29 December 2023
EDX Medical Group, plc ("EDX Medical", the "Company" or the
"Group"), which develops innovative digital diagnostic products and
services for the personalised treatment for cancer, heart disease
and infectious diseases, today announces that Dr Michael Hudson,
chief executive officer of the Company, purchased a total of
350,000 ordinary shares in the Company on December 29, 2023, at an
average price per share of 5.8071 pence. Following these purchases,
Dr Hudson owns 20,350,000 ordinary shares, representing 6.76% of
the issued share capital.
The directors of the Company accept responsibility for the
contents of this announcement.
Contacts:
EDX Medical plc
Dr Mike Hudson (Chief Executive
Officer) +44 (0)7812 345 301
Oberon Capital
Nick Lovering (Corporate
Adviser)
Adam Pollock (Corporate
Broking)
Mike Seabrook (Corporate
Broking) +44 (0)20 3179 5300
Media House International
Ramsay Smith +44 (0)7788 414856
ramsay@mediahouse.co.uk
Gary McQueen + 44 (0)7834 694609
gary@mediahouse.co.uk
About EDX Medical Group plc
EDX Medical Group plc ("EDX Medical") develops innovative
digital diagnostic products and services, enabling cost effective
and timely delivery of personalised treatment for cancer, heart
disease and infectious diseases. The company is listed on the AQSE
Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Chris Evans, OBE, a
very successful medical and life sciences entrepreneur with more
than 35 years of experience building innovative life sciences
companies.
By translating clinical insights into pragmatic solutions
combining advanced biological and digital technologies, EDX Medical
seeks to cost-effectively improve the detection and
characterisation of disease in order to select personal treatment
in a timely fashion.
Early disease detection and biologically-based personal
treatment is considered to be the most impactful way of reducing
deaths and lowering the cost of healthcare globally.
EDX Medical has established expertise in the design,
development, validation and sourcing of diagnostic testing
solutions to ISO 13485 and key laboratory tests performed by the
Company have been accredited to ISO 15189 by the United Kingdom
Accreditation Service (UKAS).
EDX Medical Group operates a molecular diagnostics and genomics
laboratory in Cambridge, UK, a Point of Care test development group
in Oxford (Hutano Diagnostics Ltd) and Torax Biosciences Ltd in
Ireland.
Learn more: www.edxmedical.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXFESFMUEDSEEE
(END) Dow Jones Newswires
January 02, 2024 02:00 ET (07:00 GMT)
Grafico Azioni EDX Medical (AQSE:EDX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni EDX Medical (AQSE:EDX)
Storico
Da Nov 2023 a Nov 2024
